Nothing Special   »   [go: up one dir, main page]

WO2009127830A1 - Compositions for the treatment of lice - Google Patents

Compositions for the treatment of lice Download PDF

Info

Publication number
WO2009127830A1
WO2009127830A1 PCT/GB2009/000982 GB2009000982W WO2009127830A1 WO 2009127830 A1 WO2009127830 A1 WO 2009127830A1 GB 2009000982 W GB2009000982 W GB 2009000982W WO 2009127830 A1 WO2009127830 A1 WO 2009127830A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
lice
composition according
ectoparasitosis
treatment
Prior art date
Application number
PCT/GB2009/000982
Other languages
French (fr)
Inventor
Marco Mastrodonato
Roberto Ciattini
Original Assignee
Sinclair Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinclair Pharmaceuticals Limited filed Critical Sinclair Pharmaceuticals Limited
Priority to AU2009237483A priority Critical patent/AU2009237483B2/en
Priority to CN2009801133578A priority patent/CN102006858A/en
Priority to CA2721649A priority patent/CA2721649A1/en
Priority to EP09731992A priority patent/EP2296623A1/en
Publication of WO2009127830A1 publication Critical patent/WO2009127830A1/en
Priority to IL208624A priority patent/IL208624A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides

Definitions

  • the present invention relates to compositions for treating lice infestations.
  • Background to the Invention Infestation of the human body by lice is a prevalent social and health problem in many countries. There are three anatomically distinct types of lice that infest humans, namely head lice, body lice and crab lice.
  • Head lice are small hard-shelled obligate ectoparasites that spend their entire life on the human scalp and feed exclusively on human blood.
  • a female louse has a life span of 4 weeks, during which time it lays 50-100 eggs. Eggs are attached firmly to the hair shaft using chitin secreted by the female. The eggs hatch after 6-9 days, and the nymph emerges leaving behind the nonviable shell or "nit". Following three cycles of moulting, the nymph develops into an adult louse capable of reproducing. Head lice infestations are most common in children aged 4-11 , and are more prevalent in females than in males. Lice are spread by direct contact with an infested person.
  • head lice can be signalled by itching caused by an allergic reaction to louse saliva. There may also be visual evidence of the presence of lice, eggs or nits.
  • the objective when treating head lice infestations must be to free the host of eggs, nymphs, lice and nits, for the continued presence of the latter can only serve to confuse later diagnosis. It is preferable that the treatment be easy to carry out, inexpensive, and associated with minimal side-effects.
  • Conventional head lice management usually involves the use of neurotoxic insecticide lotions in combination with wet combing.
  • Combing using a fine-toothed plastic comb for the detection and removal of adult lice and a metal comb for eggs and nits, is viewed as a safe method of elimination but is a laborious process and a heavy burden on parents.
  • Commonly used insecticidal treatments, or pediculicides are generally pyrethroid-based (e.g. Full Marks®), malathion-based (e.g. Derbac-M®) or carbaryl-based (e.g. Carylderm®).
  • Pyrethroids such as permethrin and phenothrin, are synthetic axionic poisons which cause nervous hyper-excitability leading to death.
  • Malathion is an organophosphate parasympathomimetic which binds irreversibly to cholinesterase.
  • Carbaryl (1-naphthyl methylcarbamate) is also a cholinesterase inhibitor.
  • Dimeticone-based products kill lice by inhibiting their ability to excrete surplus water. They are not traditional insecticides and have a good safety profile and are therefore recommended for pregnant or breastfeeding women. However, dimeticone is not thought to be effective in removing eggs from the host.
  • the present invention relates to compositions suitable for use in the treatment of lice infestations.
  • the present invention is also directed to methods of administering a composition such that lice, eggs and nits are eradicated from the host.
  • a composition comprises glycerine, petrolatum and VP-hexadecene copolymer.
  • such a composition is used in therapy, particularly for the topical treatment of ectoparasitosis.
  • a method of treating ectoparasitosis comprises contacting the infested area of the subject with the composition of the invention.
  • the present invention provides a composition that is useful in the topical treatment of ectoparasitosis, and in particular the treatment of pediculosis.
  • ectoparasite is defined herein as a parasite that lives on the external surface of a host.
  • ectoparasitosis refers to an infestation of ectoparasites.
  • pediculosis refers to a lice infestation.
  • the three genera of lice which affect humans are Pediculosis humanus capitis (head lice), Pediculosis humanus corporis (body lice) and Pthirus pubis (crab lice).
  • the composition of the present invention is intended for use in the treatment of mammalian ectoparasitosis.
  • the ectoparasitosis to be treated by use of the composition is pediculosis. More preferably, the pediculosis is a human lice infestation, and most preferably a head lice infestation.
  • pediculicide refers to a pharmaceutical composition for the treatment of pediculosis.
  • the terms "subject” and “host” are used interchangeably and refer to a mammal including a non-primate (e.g. a cow, pig, horse, cat, dog, rat and mouse) and a primate (e.g. a monkey and a human), and preferably a human.
  • a non-primate e.g. a cow, pig, horse, cat, dog, rat and mouse
  • a primate e.g. a monkey and a human
  • composition of the invention is a liquid formulation comprising glycerine, petrolatum and vinylpyrrolidine (VP)/hexadecene copolymer.
  • glycol is intended to encompass all terms used to describe the compound propane-1 ,2,3-triol which has the chemical formula HOCH 2 CH(OH)CH 2 OH.
  • Petrolatum refers to pharmaceutical-grade or cosmetic-grade petrolatum and includes all synonyms including petroleum jelly and paraffin jelly. Petrolatum is a colourless to yellowish-white non-polar hydrocarbon mixture obtained by fractional distillation of petroleum and is commercially available under the brand name Vaseline®.
  • VP/hexadecene copolymer refers to the coplymer of vinylpyrrolidine and long chain ⁇ -olefins. VP/hexadecene copolymer is a pale yellow viscous liquid commonly added to cosmetic products for its wear-resistance and moisture barrier-forming properties and is available commercially as Antaron®V-216 or Ganex®V-216.
  • composition of the invention also comprises either, or both, pectin and xanthan gum.
  • pectin' refers to a heteropolysaccharide derived from the cell wall of higher terrestrial plants that is commonly used as a gelling agent, a thickening agent and a stabilizer in food.
  • the characteristic structure is a linear homogalacturonan with substituted regions of (1-2)-linked L-rhamnose.
  • Isolated pectin is a white to light-brown powder and has a molecular weight of typically 60-130 000 g/mol, varying with origin and extraction conditions.
  • 'xanthan gum' refers to a polysaccharide produced during the fermentation of glucose or sucrose by the Xanthomonas campestris bacterium. Xanthan gum is useful industrially since a very small quantity of gum (in the order of 0.5-1%) is capable of producing a large increase in the viscosity of a liquid.
  • the composition comprises 0.1-5% w/w glycerine, 0.1-5% w/w petrolatum, 0.1-5% w/w VP-hexadecene polymer, 0.05-2 % w/w pectin and 0.05- 2 % w/w xanthan gum.
  • the composition also comprises a surfactant, preferably an anionic surfactant.
  • Suitable cosmetic-grade surfactants are known in the art and include sodium dodecasulphate (SDS), ammonium lauryl sulphate, sodium laureth sulphate, soaps and fatty acid salts.
  • the pediculicide of the invention is a liquid formulation, preferably an aqueous lotion.
  • Ingredients of the formulation include, but are not limited to, water, cosmetic-grade emollients such as cetearyl alcohol, emulsifiers such as steareth-21 , anti-static agents such as behentrimonium chloride, humectants such as propylene glycol, sorbitol, and glyceryl stearate citrate , moisturisers such as propylene glycol, preservatives such as parabens and phenoxyethanol and fragrant esters.
  • the pediculicide is applied to the dry hair of an infested subject in a quantity sufficient to cover the entire area. It is preferable for the hair to then be wrapped in a plastic wrap or 'cling film'.
  • the composition adheres to the hair shaft, forming a continuous impermeable film which prevents the lice and eggs from obtaining oxygen, thereby causing suffocation and death.
  • the composition is left on the hair for a length of time sufficient to kill the lice and eggs by suffocation action.
  • the composition is left on the hair for between 40 to 80 minutes, more preferably for 60 minutes, and then removed by rinsing with water.
  • the presence of an anionic surfactant facilitates removal of the solution.
  • Dead lice and eggs can be removed by wet combing the hair using a fine-toothed comb (teeth 0.2 to 0.3mm apart).
  • subjects should preferably be treated twice a day for up to three days.
  • the treatment is repeated after fifteen days to ensure eradication of any lice or eggs that may have persisted following the first treatment. Since the pediculicide of the invention employs a physical rather than biochemical mode of action, lice populations are not able to develop resistance and therefore the efficacy of the treatment will not decline over time.
  • Example 1 The following efficacy study was performed on 13 subjects suffering from pediculosis. 11 of the subjects were female and 2 were male, and all were between the ages of 8 and 40 years old. In all subjects lice were found close to the scalp and itching was reported.
  • Two versions of the pediculicide composition of the invention were prepared, one having a creamy consistency and one having a fluid consistency.
  • the creamy version of the pediculicide was tested on 5 subjects and the fluid version was tested on 8 subjects.
  • the components of the composition is as set out in Table 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

The present invention provides a composition comprising glycerine, petrolatum and VP/hexadecane copolymer that is suitable for use in the treatment of lice infections. The present invention also provides methods of administering a composition such that lice, eggs and nits are eradicated from the host.

Description

COMPOSITIONS FORTHE TREATMENT OF LICE
Field of the Invention
The present invention relates to compositions for treating lice infestations. Background to the Invention Infestation of the human body by lice is a prevalent social and health problem in many countries. There are three anatomically distinct types of lice that infest humans, namely head lice, body lice and crab lice.
Head lice are small hard-shelled obligate ectoparasites that spend their entire life on the human scalp and feed exclusively on human blood. A female louse has a life span of 4 weeks, during which time it lays 50-100 eggs. Eggs are attached firmly to the hair shaft using chitin secreted by the female. The eggs hatch after 6-9 days, and the nymph emerges leaving behind the nonviable shell or "nit". Following three cycles of moulting, the nymph develops into an adult louse capable of reproducing. Head lice infestations are most common in children aged 4-11 , and are more prevalent in females than in males. Lice are spread by direct contact with an infested person. The presence of head lice can be signalled by itching caused by an allergic reaction to louse saliva. There may also be visual evidence of the presence of lice, eggs or nits. The objective when treating head lice infestations must be to free the host of eggs, nymphs, lice and nits, for the continued presence of the latter can only serve to confuse later diagnosis. It is preferable that the treatment be easy to carry out, inexpensive, and associated with minimal side-effects.
Conventional head lice management usually involves the use of neurotoxic insecticide lotions in combination with wet combing. Combing, using a fine-toothed plastic comb for the detection and removal of adult lice and a metal comb for eggs and nits, is viewed as a safe method of elimination but is a laborious process and a heavy burden on parents. Commonly used insecticidal treatments, or pediculicides, are generally pyrethroid-based (e.g. Full Marks®), malathion-based (e.g. Derbac-M®) or carbaryl-based (e.g. Carylderm®). Pyrethroids, such as permethrin and phenothrin, are synthetic axionic poisons which cause nervous hyper-excitability leading to death. Malathion is an organophosphate parasympathomimetic which binds irreversibly to cholinesterase. Carbaryl (1-naphthyl methylcarbamate) is also a cholinesterase inhibitor.
However, there is evidence that these current chemical treatments fail to resolve the pathology of lice infestations and are significantly disadvantageous because they are associated with side-effects such as scalp irritation and are highly toxic if ingested orally. Carbaryl is also potentially carcinogenic.
Furthermore, there is also evidence of lice populations developing resistance to many of the commonly used pediculicides and concern about the safety of neurotoxin-based treatments, particularly when used to treat very young subjects.
Alternative treatments containing essential oils, herbal extracts or homeopathic tinctures are also available, although there is no scientific evidence to demonstrate their efficacy. Dimeticone-based products kill lice by inhibiting their ability to excrete surplus water. They are not traditional insecticides and have a good safety profile and are therefore recommended for pregnant or breastfeeding women. However, dimeticone is not thought to be effective in removing eggs from the host.
Therefore, there is a need for the development of new compositions which enable the safe and effective treatment of head lice and avoid the problems of induced resistance. Summary of the Invention
The present invention relates to compositions suitable for use in the treatment of lice infestations. The present invention is also directed to methods of administering a composition such that lice, eggs and nits are eradicated from the host.
According to a first aspect of the invention, a composition comprises glycerine, petrolatum and VP-hexadecene copolymer.
According to a second aspect of the invention, such a composition is used in therapy, particularly for the topical treatment of ectoparasitosis. According to a third aspect of invention, a method of treating ectoparasitosis comprises contacting the infested area of the subject with the composition of the invention. Detailed Description of the Invention
The present invention provides a composition that is useful in the topical treatment of ectoparasitosis, and in particular the treatment of pediculosis. The term "ectoparasite" is defined herein as a parasite that lives on the external surface of a host. The term "ectoparasitosis" refers to an infestation of ectoparasites.
As used herein, the term "pediculosis" refers to a lice infestation. The three genera of lice which affect humans are Pediculosis humanus capitis (head lice), Pediculosis humanus corporis (body lice) and Pthirus pubis (crab lice).
The composition of the present invention is intended for use in the treatment of mammalian ectoparasitosis. In a preferred embodiment, the ectoparasitosis to be treated by use of the composition is pediculosis. More preferably, the pediculosis is a human lice infestation, and most preferably a head lice infestation.
As used herein, the term "pediculicide" refers to a pharmaceutical composition for the treatment of pediculosis.
As used herein, the terms "subject" and "host" are used interchangeably and refer to a mammal including a non-primate (e.g. a cow, pig, horse, cat, dog, rat and mouse) and a primate (e.g. a monkey and a human), and preferably a human.
The composition of the invention is a liquid formulation comprising glycerine, petrolatum and vinylpyrrolidine (VP)/hexadecene copolymer.
As used herein, the term "glycerine" is intended to encompass all terms used to describe the compound propane-1 ,2,3-triol which has the chemical formula HOCH2CH(OH)CH2OH.
As used herein, the term "petrolatum" refers to pharmaceutical-grade or cosmetic-grade petrolatum and includes all synonyms including petroleum jelly and paraffin jelly. Petrolatum is a colourless to yellowish-white non-polar hydrocarbon mixture obtained by fractional distillation of petroleum and is commercially available under the brand name Vaseline®.
As used herein, the term "VP/hexadecene copolymer" refers to the coplymer of vinylpyrrolidine and long chain α-olefins. VP/hexadecene copolymer is a pale yellow viscous liquid commonly added to cosmetic products for its wear-resistance and moisture barrier-forming properties and is available commercially as Antaron®V-216 or Ganex®V-216.
In a preferred embodiment the composition of the invention also comprises either, or both, pectin and xanthan gum.
As used herein, the term 'pectin' refers to a heteropolysaccharide derived from the cell wall of higher terrestrial plants that is commonly used as a gelling agent, a thickening agent and a stabilizer in food. The characteristic structure is a linear homogalacturonan with substituted regions of (1-2)-linked L-rhamnose. Isolated pectin is a white to light-brown powder and has a molecular weight of typically 60-130 000 g/mol, varying with origin and extraction conditions.
As used herein, the term 'xanthan gum' refers to a polysaccharide produced during the fermentation of glucose or sucrose by the Xanthomonas campestris bacterium. Xanthan gum is useful industrially since a very small quantity of gum (in the order of 0.5-1%) is capable of producing a large increase in the viscosity of a liquid.
Typically, the composition comprises 0.1-5% w/w glycerine, 0.1-5% w/w petrolatum, 0.1-5% w/w VP-hexadecene polymer, 0.05-2 % w/w pectin and 0.05- 2 % w/w xanthan gum. In a further preferred embodiment, the composition also comprises a surfactant, preferably an anionic surfactant. Suitable cosmetic-grade surfactants are known in the art and include sodium dodecasulphate (SDS), ammonium lauryl sulphate, sodium laureth sulphate, soaps and fatty acid salts.
In a preferred embodiment, the pediculicide of the invention is a liquid formulation, preferably an aqueous lotion.
Ingredients of the formulation include, but are not limited to, water, cosmetic-grade emollients such as cetearyl alcohol, emulsifiers such as steareth-21 , anti-static agents such as behentrimonium chloride, humectants such as propylene glycol, sorbitol, and glyceryl stearate citrate , moisturisers such as propylene glycol, preservatives such as parabens and phenoxyethanol and fragrant esters. The formulation may optionally further comprise cosmetic- grade dyes and colour agents. Table 1 provides a non-limiting example of the composition according to the invention. Table 1 :
Figure imgf000006_0001
According to a further embodiment of the invention, the pediculicide is applied to the dry hair of an infested subject in a quantity sufficient to cover the entire area. It is preferable for the hair to then be wrapped in a plastic wrap or 'cling film'. The composition adheres to the hair shaft, forming a continuous impermeable film which prevents the lice and eggs from obtaining oxygen, thereby causing suffocation and death.
In a preferred embodiment, the composition is left on the hair for a length of time sufficient to kill the lice and eggs by suffocation action. In a preferred embodiment, the composition is left on the hair for between 40 to 80 minutes, more preferably for 60 minutes, and then removed by rinsing with water. The presence of an anionic surfactant facilitates removal of the solution. Dead lice and eggs can be removed by wet combing the hair using a fine-toothed comb (teeth 0.2 to 0.3mm apart). In order to ensure effective removal of all lice and nits, subjects should preferably be treated twice a day for up to three days. In a more preferred embodiment, the treatment is repeated after fifteen days to ensure eradication of any lice or eggs that may have persisted following the first treatment. Since the pediculicide of the invention employs a physical rather than biochemical mode of action, lice populations are not able to develop resistance and therefore the efficacy of the treatment will not decline over time.
The present invention will now be exemplified by the following non- limiting example: Example The following efficacy study was performed on 13 subjects suffering from pediculosis. 11 of the subjects were female and 2 were male, and all were between the ages of 8 and 40 years old. In all subjects lice were found close to the scalp and itching was reported.
Two versions of the pediculicide composition of the invention were prepared, one having a creamy consistency and one having a fluid consistency. The creamy version of the pediculicide was tested on 5 subjects and the fluid version was tested on 8 subjects. The components of the composition is as set out in Table 1.
In each case, the pediculicide was applied to the entire crop of dry hair, which was then wrapped in cling film and left for approximately 2 hours. The product was then removed by normal shampooing and then the hair was combed with a fine toothed comb. This process was repeated after one week and all subjects were inspected for the presence of lice one month after the first application. The results of the study are summarised in Table 2: Table 2:
Figure imgf000008_0001
These results show that the removal of lice immediately following the first application of the composition was seen in 8 subjects. After one week, only empty shells and dry nits were observed, and these were away from the scalp in all subjects. Inspection one month after the first application showed that all subjects were negative for the presence of lice or nits. One the whole, the composition proved satisfactory to all, without any manifestation of intolerance, itching, irritation or burning sensation at the time of application.

Claims

Claims
1. A composition comprising glycerine, petrolatum and VP/hexadecene copolymer.
2. A composition according to claim 1 , further comprising pectin.
3. A composition according to claim 1 or claim 2, further comprising xanthan gum.
4. A composition according to any preceding claim, further comprising a surfactant.
5. A composition according to claim 4, wherein the surfactant is an anionic surfactant.
6. A composition according to any preceding claim, comprising a concentration of 0.1-5% w/ w glycerine, 0.1-5% w/ w petrolatum, 0.1-5% w/ w VP/hexadecene copolymer, 0.05-2% w/w pectin and 0.05-2% w/w xanthan gum.
7. A pediculicide comprising a composition according to any preceding claim.
8. A pediculicide according to claim 7, wherein the composition is a liquid formulation.
9. A pediculicide according to claim 8, wherein the formulation is an aqueous lotion.
10. A composition according to any of claims 1 to 6, for use in therapy.
11. A composition according to claim 10, wherein the therapy is topical treatment of ectoparasitosis in mammals.
12. A composition according to claim 11 , wherein the ectoparasitosis is in a human subject.
13. A composition according to claim 12, wherein the ectoparasitosis is pediculosis.
14. A composition according to claim 13, wherein the pediculosis is head lice.
15. A method of treating ectoparasitosis, comprising contacting the infested area of a subject with the composition according to any of claims 1 to 6.
16. A method according to claim 15, wherein the ectoparasitosis is pediculosis.
17. A method according to claim 16, wherein the pediculosis is head lice.
18. A method according to claim 17, wherein the hair is dry at the time of contact.
19. A method according to claim 18, wherein the composition is in contact with the hair for a length of time sufficient to kill the lice by suffocation.
20. A method according to claim 19, wherein the composition is in contact with the hair for 40 to 80 minutes per treatment.
21. A method according to claim 20, wherein treatment is repeated twice a day for up to three days.
PCT/GB2009/000982 2008-04-16 2009-04-16 Compositions for the treatment of lice WO2009127830A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2009237483A AU2009237483B2 (en) 2008-04-16 2009-04-16 Compositions for the treatment of lice
CN2009801133578A CN102006858A (en) 2008-04-16 2009-04-16 Compositions for the treatment of lice
CA2721649A CA2721649A1 (en) 2008-04-16 2009-04-16 Compositions for the treatment of lice
EP09731992A EP2296623A1 (en) 2008-04-16 2009-04-16 Compositions for the treatment of lice
IL208624A IL208624A0 (en) 2008-04-16 2010-10-11 Compositions for the treatment of lice

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0806948.6A GB0806948D0 (en) 2008-04-16 2008-04-16 Composition
GB0806948.6 2008-04-16

Publications (1)

Publication Number Publication Date
WO2009127830A1 true WO2009127830A1 (en) 2009-10-22

Family

ID=39472220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/000982 WO2009127830A1 (en) 2008-04-16 2009-04-16 Compositions for the treatment of lice

Country Status (8)

Country Link
EP (1) EP2296623A1 (en)
KR (1) KR20110015524A (en)
CN (1) CN102006858A (en)
AU (1) AU2009237483B2 (en)
CA (1) CA2721649A1 (en)
GB (1) GB0806948D0 (en)
IL (1) IL208624A0 (en)
WO (1) WO2009127830A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20090122A1 (en) * 2009-03-23 2010-09-24 Marco Nicoletti COMPOSITION FOR COSMETIC BASIC CREAM AND ITS PREPARATION PROCEDURE
LU92931B1 (en) * 2015-12-24 2017-07-20 Pihuit S A COMPOSITION AND METHOD OF PEST CONTROL
WO2017198241A1 (en) * 2016-05-19 2017-11-23 Vakos Xt A.S. A lice killing agent
CZ307442B6 (en) * 2017-04-18 2018-08-22 Vakos Xt A.S. A composition for killing lice

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB564729A (en) * 1940-06-26 1944-10-11 Cooper Mcdougall & Robertson Improved insecticide
GB572310A (en) * 1942-12-31 1945-10-02 Mckesson & Robbins Inc Parasiticides
WO2000072814A1 (en) * 1999-05-27 2000-12-07 Eduardo Zancaner Composition for cleaning and removing parasites from the hair
WO2002053120A2 (en) * 2001-01-08 2002-07-11 Beiersdorf Ag Cosmetic and dermatological light protection formulations containing benzotriazole derivatives and surfactant sucrose esters
US20050106190A1 (en) * 2001-12-18 2005-05-19 Rolf Kawa Cosmetic and/or pharmaceutical emulsions
WO2007085899A2 (en) * 2005-07-06 2007-08-02 Foamix Ltd. Foamable arthropocidal composition for tropical application

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB564729A (en) * 1940-06-26 1944-10-11 Cooper Mcdougall & Robertson Improved insecticide
GB572310A (en) * 1942-12-31 1945-10-02 Mckesson & Robbins Inc Parasiticides
WO2000072814A1 (en) * 1999-05-27 2000-12-07 Eduardo Zancaner Composition for cleaning and removing parasites from the hair
WO2002053120A2 (en) * 2001-01-08 2002-07-11 Beiersdorf Ag Cosmetic and dermatological light protection formulations containing benzotriazole derivatives and surfactant sucrose esters
US20050106190A1 (en) * 2001-12-18 2005-05-19 Rolf Kawa Cosmetic and/or pharmaceutical emulsions
WO2007085899A2 (en) * 2005-07-06 2007-08-02 Foamix Ltd. Foamable arthropocidal composition for tropical application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FOWLER J F: "Allergic contact dermatitis to polyvinylpyrrolidone/hexadecene copolymer", AMERICAN JOURNAL OF CONTACT DERMATITIS, SAUNDERS, HARCOURT BRACE JOVANOVICH, PHILADELPHIA, PA, US, vol. 6, no. 4, 1 December 1995 (1995-12-01), pages 243 - 244, XP004528385, ISSN: 1046-199X *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20090122A1 (en) * 2009-03-23 2010-09-24 Marco Nicoletti COMPOSITION FOR COSMETIC BASIC CREAM AND ITS PREPARATION PROCEDURE
LU92931B1 (en) * 2015-12-24 2017-07-20 Pihuit S A COMPOSITION AND METHOD OF PEST CONTROL
WO2017198241A1 (en) * 2016-05-19 2017-11-23 Vakos Xt A.S. A lice killing agent
CZ307442B6 (en) * 2017-04-18 2018-08-22 Vakos Xt A.S. A composition for killing lice

Also Published As

Publication number Publication date
AU2009237483A1 (en) 2009-10-22
KR20110015524A (en) 2011-02-16
EP2296623A1 (en) 2011-03-23
AU2009237483B2 (en) 2012-05-10
GB0806948D0 (en) 2008-05-21
IL208624A0 (en) 2010-12-30
CA2721649A1 (en) 2009-10-22
CN102006858A (en) 2011-04-06

Similar Documents

Publication Publication Date Title
US6541455B2 (en) Methods and kits for removing, treating, or preventing lice with driable pediculostatic agents
DE60006556T2 (en) METHOD AND COMPOSITION FOR COMBATING ARTHROPODES
US6607716B1 (en) Pediculicidal compositions, a kit, and methods of use
US20060121073A1 (en) Topical gel formulation comprising insecticide and its preparation thereof
US20080118585A1 (en) Natural compositions for killing parasites on a companiion animal
EP2750680B1 (en) Composition for treating lice infestation
US9955695B2 (en) Pediculicide/ovicide composition
AU2009237483B2 (en) Compositions for the treatment of lice
EP2081428B1 (en) Antipediculosis composition having a lice-suffocating activity
EP3424321A1 (en) Compounds for treating ectoparasite infestation
EP2470006B1 (en) Use of a microemulsion for controlling lice
WO2024201283A1 (en) Insecticidal and arachnidicidal compositions and uses thereof
US20060084632A1 (en) Topical gel formulation comprising organophosphate insecticide and its preparation thereof
US20120172338A1 (en) Topical gel formulation comprising organophosphate insecticide and its preparation thereof
RU2340181C1 (en) Insectoacaricide agent insektal-plus
DE69709317T2 (en) ANTISEPTIC COMPOSITIONS BASED ON CHLOROBUTANOL AND CHLORHEXIDINE
WO2024218775A1 (en) Compositions for treating lice infestations
US20050165104A1 (en) Biocidal agents and veterinary methods
FR3075040A1 (en) PEST CONTROL COMPOSITION FOR EXTERNAL USE
Sakr et al. Assessment of Essential Oils Treatment of Neem Extract Versus Ivermectin Against Sarcoptes scabiei In Rabbit Flocks
WO2001012173A1 (en) Low concentration pest treatment composition and method
Patyk Practical evaluation of insecticides and their application
WO2019115980A1 (en) Antiparasitic composition for external use
FR3042119A1 (en) VETERINARY COMPOSITIONS FOR CONTROLLING PHLEBOTOMAS
FR2691358A1 (en) Undecylenic and undecanoic acid derivs.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980113357.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09731992

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12010502317

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 7251/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2721649

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009237483

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107023989

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009731992

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009237483

Country of ref document: AU

Date of ref document: 20090416

Kind code of ref document: A